Trial Profile
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs CD154 gene therapy (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Memgen